Cost
Tirzepatide Cost
Tirzepatide cost depends on whether you use an approved brand or a compounded preparation, whether you have coverage, and which fees a telehealth provider adds. Across the 5 providers in our dataset with a normalisable price, recurring compounded costs range from about $125 to $298 per month — but those figures are not all measured on the same basis.
Key takeaways
- Brand and compounded pricing differ by a large margin without insurance coverage.
- Normalised compounded provider costs in our dataset span roughly $125 to $298 per month.
- Advertised medication prices frequently exclude mandatory membership, consultation, or shipping fees.
- The relevant figure is recurring cost over years, because stopping produces regain (SURMOUNT-4).
- Dose increases can change cost at some providers — a term that is unverified for most.
| Brand cash price | Substantially higher than compounded; varies with programme eligibility |
|---|---|
| Compounded range (normalised) | About $125 to $298 per month in our dataset |
| Common hidden costs | Membership, consultation, shipping, dose surcharges |
| Planning horizon | Years — maintenance is required to hold results |
| Providers with normalisable pricing | 5 of 24 |
| Price verified | 2026-07-20 |
Why is a single tirzepatide price impossible to quote?
Because four variables move independently: brand versus compounded, insurance coverage and tier, manufacturer savings eligibility, and the fee structure a telehealth provider layers on top. A person with commercial coverage and a savings card and a person paying cash for a compounded product are not buying comparable things at comparable prices.
What this site can do is normalise the compounded telehealth market so those providers can be compared against each other honestly.
What is the most common way tirzepatide pricing misleads?
Advertising a medication price while billing a separate mandatory membership. A provider advertising $99 monthly with a $79 membership costs about $178; one publishing $186 all-in costs $186. The advertised figures suggest an $87 difference in one direction; the actual figures differ by $8 in the other.
Introductory first-month pricing is the second most common. A discounted first month tells you almost nothing about a treatment expected to continue for years.
What should you calculate before committing?
The recurring monthly cost including every mandatory fee, multiplied by twelve and twenty-four months, plus what happens if your dose increases. Then check what you lose if you stop early under the cancellation terms.
The true-cost calculator does this arithmetic.
What the evidence shows
- Normalised recurring costs for providers whose fee structures are captured.
- That advertised prices frequently exclude mandatory fees.
What the evidence does not show
- A single accurate tirzepatide price — it depends on too many individual variables.
- Brand pricing for your specific coverage — check with your plan and pharmacy.
Related: Cost without insurance · Most affordable programs
What does the market actually charge?
| Group | $/month |
|---|---|
| TRYM Health | 125 |
| NexLife | 186 |
| Fridays | 240 |
| Mochi Health | 278 |
| Eden | 298 |
| Component | Amount | Running total |
|---|---|---|
| Advertised medication price | $99 | $99 |
| Monthly membership fee | $79 | $178 |
| Consultation fee | $0 | $178 |
| Shipping | $0 | $178 |
| Series | Start | 6 mo | 12 mo | 18 mo | 24 mo |
|---|---|---|---|---|---|
| TRYM Health | 0$ | 750.0$ | 1500.0$ | 2250.0$ | 3000.0$ |
| NexLife | 0$ | 1116.0$ | 2232.0$ | 3348.0$ | 4464.0$ |
| Fridays | 0$ | 1440.0$ | 2880.0$ | 4320.0$ | 5760.0$ |
How has the cost picture changed since compounding closed?
During the shortage, compounded programmes undercut the approved product substantially and the practical question was which compounded seller to use. That question has closed. The cost picture now runs through coverage, manufacturer programmes, and the direct cash channel, and the spread between them is wide.
| Pathway | Product | Monthly cost | Evidence status | Principal condition |
|---|---|---|---|---|
| Zepbound self-pay via LillyDirect | Zepbound single-dose vial | $299–$449 | Verified | Requires a valid on-label Zepbound prescription. |
| Zepbound at retail pharmacy without coverage | Zepbound | $1,086 | Partially verified | Approximate list price; actual retail cost varies by pharmacy and region. |
| Zepbound savings card (commercially insured) | Zepbound | $25 | Partially verified | Requires commercial insurance with a covered weight-management benefit. |
| Mounjaro self-pay | Mounjaro | $499 | Partially verified | Type 2 diabetes indication. |
| Lilly Cares patient assistance (Mounjaro) | Mounjaro | $0 | Partially verified | For income-eligible uninsured patients at or below 400% of the federal poverty level. |
| Group | $/month |
|---|---|
| Zepbound self-pay via LillyDirect | 299 |
| Zepbound at retail pharmacy withou | 1086 |
| Zepbound savings card (commerciall | 25 |
| Mounjaro self-pay | 499 |
| Lilly Cares patient assistance (Mo | 0 |
The single most consequential fact for a cash-paying reader is the gap between the manufacturer's direct channel and retail. Zepbound self-pay through LillyDirect starts at $299 per month for the starting dose, against a retail list price in the region of $1,086. That is not a discount in the ordinary sense — it is a different distribution channel that bypasses the pharmacy benefit manager, and it is cash-only, so it cannot be combined with insurance.
What should someone previously on a compounded programme do now?
Speak to the prescriber who issued the prescription before making any change. The transition question is clinical as well as financial: dose equivalence, supply continuity, and whether an approved product is covered all matter, and none of them can be settled from a website.
Financially, the realistic expectation is an increase. Compounded programmes were priced below the approved product, and the pathways above are what remain. Anyone budgeting should model the approved-product cost over the multi-year horizon the withdrawal evidence implies rather than assuming a compounded price will remain obtainable.
Which pathway applies to which reader?
If you have commercial insurance with a covered weight-management benefit, the savings card route is usually cheapest, and the practical work is securing coverage rather than finding a price. If you have commercial insurance without that benefit, the decision is between appealing the exclusion and paying cash through the manufacturer channel. If you are uninsured or paying cash by choice, the manufacturer channel is the main option.
If you are on Medicare or Medicaid, manufacturer savings cards are generally unavailable, though cash-pay channels can still be used with your own money rather than billed to the plan. Coverage rules in this area are changing and should be confirmed against your own plan documents rather than assumed.
- Only the LillyDirect self-pay figures are verified against a first-party source; the remaining figures are labelled partially verified and should be confirmed directly.
- Manufacturer programme terms, caps, and eligibility change frequently and without notice.
- Insurance coverage for weight management varies by plan, employer, and state, and a national statement cannot describe your specific benefit.
- Refill-window conditions attach to the lowest self-pay prices at higher doses; missing the window raises the cost materially.
| Product | Regulatory status | What that means for availability |
|---|---|---|
| Zepbound (tirzepatide) | FDA approved for chronic weight management | Available by prescription through normal pharmacy channels |
| Mounjaro (tirzepatide) | FDA approved for type 2 diabetes | Available by prescription through normal pharmacy channels |
| Compounded tirzepatide injection | Not FDA approved; shortage resolved, enforcement discretion ended | Routine compounding no longer permitted as an essentially-a-copy product |
| Compounded oral, sublingual, ODT or troche tirzepatide | Not FDA approved in any form | Never covered by shortage-era compounding; no approved oral tirzepatide product exists |
| Research-grade or grey-market tirzepatide | Not a medicine; outside the regulated supply chain | No pharmacy accountability, no verified identity, purity, or sterility |
Why is tirzepatide pricing so hard to compare?
Four structural features of this market make direct comparison difficult, and none of them is accidental. Prices are frequently advertised as a starting figure that applies to a subset of doses or commitment lengths. Medication and service are often billed separately, so the headline covers part of the cost. Introductory rates differ from recurring rates, and the introductory figure is the one displayed. And commitment tiers convert a monthly price into a prepayment, which changes what the number means.
The combined effect is that two advertised figures can differ by a factor of two while the actual recurring costs are nearly identical, or appear nearly identical while the actual costs differ substantially. This is why every figure on this site is normalised before it is compared, and why providers whose figures cannot be normalised are excluded rather than estimated.
| Cost component | Typically advertised? | Typically included in the headline? | Effect on real cost |
|---|---|---|---|
| Medication | Yes | Sometimes | The base figure |
| Membership or programme fee | Sometimes | Rarely | Commonly $40-$80 per month |
| Initial consultation | Sometimes | Rarely | One-off, but can be substantial |
| Shipping | Sometimes | Varies | Small but recurring |
| Dose surcharge above a threshold | Rarely | Almost never | Can change which provider is cheapest |
| Laboratory work | Rarely | No | Variable, sometimes billed to insurance |
| Renewal after introductory period | Rarely displayed | No | Frequently the largest single jump |
| Component | Amount | Running total |
|---|---|---|
| Advertised medication price | $99 | $99 |
| Recurring membership fee | $79 | $178 |
| Shipping, billed monthly | $10 | $188 |
What does treatment cost over a realistic horizon?
Because SURMOUNT-4 established that stopping produces substantial regain, the planning horizon for tirzepatide is years rather than months. A monthly difference that looks trivial compounds into a material sum across that period, and an introductory discount that looks generous becomes close to irrelevant.
| Provider | Monthly | One year | Two years | Three years |
|---|---|---|---|---|
| TRYM Health | $125 | $1,500 | $3,000 | $4,500 |
| NexLife | $186 | $2,232 | $4,464 | $6,696 |
| Fridays | $240 | $2,880 | $5,760 | $8,640 |
| Mochi Health | $278 | $3,336 | $6,672 | $10,008 |
| Eden | $298 | $3,576 | $7,152 | $10,728 |
These projections assume the price and the dose are unchanged, and neither is guaranteed. Dose coverage is unverified for most providers in this dataset, and a surcharge that applies above a dose threshold would raise the later years of every column. The projection is therefore a floor rather than a forecast.
What does this page cover, and what does it deliberately leave out?
This page addresses Brand, compounded, insurance, fees and dose and renewal, organised around the primary question of tirzepatide cost. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Brand | Covered on this page | Captured record |
| Compounded | Covered on this page | Captured record |
| Insurance | Covered on this page | Captured record |
| Fees | Covered on this page | Captured record |
| Dose and renewal | Covered on this page | Captured record |
| Individualized clinical instruction | Deliberately not covered | Belongs with your insurer and the provider |
What are the limits of what this page can tell you?
Every page on this site rests on a specific captured pricing and coverage rules, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for your insurer and the provider.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This conclusion is held open to the following evidence:
- New primary evidence bearing directly on tirzepatide cost.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 5 technical terms this page uses, including 503A, 503B, compounded, effective monthly cost — in the specific sense used above.
| 503A | A pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility. |
|---|---|
| 503B | An outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| effective monthly cost | The recurring amount actually paid each month once every mandatory fee is included. It is frequently higher than the advertised medication price, which is why this site normalises before ranking. |
| membership fee | A recurring charge separate from the medication price, common in telehealth weight programmes. It can add $40 to $80 per month and frequently reverses which provider is genuinely cheaper. |
Frequently asked questions
How much does tirzepatide cost per month?
Compounded provider costs in our dataset normalise to roughly $125-$298 per month; brand cash prices are substantially higher. Coverage changes both.
Why do advertised prices differ from what I pay?
Advertised medication prices frequently exclude mandatory membership, consultation, or shipping fees.
Is compounded always cheaper?
Usually on cash price, but the comparison changes with insurance coverage or savings-programme eligibility for the brand.
What happens to cost when my dose increases?
Some providers apply surcharges above a threshold; this term is unverified for most providers in our dataset.
What is the real long-term cost?
Recurring cost multiplied over years, since maintaining results requires continued treatment. Model it with the calculator.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.